Response to letter to editor on the article: Ge W, Chen C, Wu N et al. Hedgehog pathway inhibitor real-world treatment patterns in patients with basal cell carcinoma: a claims-based analysis. Fut. Oncol. 18(23), 2561–2572 (2022)

Click to increase image sizeClick to decrease image size

Financial disclosure

This work was funded by Regeneron Pharmaceuticals, Inc. and Sanofi. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Competing interests disclosure

W Ge, C Chen, N Wu, MG Fury and JJ Jalbert are employees and shareholders of Regeneron Pharmaceuticals, Inc. E Ruiz has received consulting fees from PellePharm, Sanofi, Regeneron Pharmaceuticals, Inc. and Leo Pharmaceuticals, and is on the consulting and advisory board for Checkpoint Therapeutics. Responsibility for all opinions, conclusions and data interpretation lies with the authors. The sponsors were involved in the study design and collection, analysis and interpretation of data, as well as data checking of information provided in the manuscript. The authors had unrestricted access to study data, were responsible for all content and editorial decisions, and received no honoraria related to the development of this publication.

Writing disclosure

Medical writing support was provided by Jonathan Latham and was funded by Regeneron Pharmaceuticals, Inc. and Sanofi.

Additional information

Funding

This work was funded by Regeneron Pharmaceuticals, Inc. and Sanofi. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.